Table 3. Uni-variate and multivariate Cox regression analyses results for evaluating variables associated with cancer specific survival in lymph node positive group.
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| Unadjusted HR | 95% CI | p-value | Adjusted HR | 95% CI | p-value | |
| Pathologic T stage | ||||||
| Non-muscle invasive (pT0/Ta/T1/CIS) | Reference | Reference | ||||
| Muscle invasive (pT2) | 1.06 | 0.27–4.25 | 0.932 | 0.69 | 0.14–3.43 | 0.655 |
| Extravesical (pT3/T4) | 3.66 | 1.12–11.97 | 0.032 | 1.34 | 0.31–5.91 | 0.695 |
| Variant histology of UC | ||||||
| Absent | Reference | Reference | ||||
| Present | 3.48 | 1.77–6.85 | <0.001 | 3.66 | 1.69–7.90 | 0.001 |
| LVI | ||||||
| Absent | Reference | Reference | ||||
| Present | 2.47 | 1.22–5.01 | 0.012 | 3.08 | 1.44–6.58 | 0.004 |
| Pathologic nodal stage | ||||||
| N1 | Reference | |||||
| N2 | 1.80 | 0.95–3.42 | 0.070 | |||
| N3 | 2.14 | 0.70–6.55 | 0.181 | |||
| Number of removed LNs (continuous) | 0.96 | 0.93–0.99 | 0.023 | 0.94 | 0.90–0.98 | 0.006 |
| Number of positive LNs (continuous) | 1.11 | 1.01–1.22 | 0.022 | 1.22 | 1.08–1.38 | 0.001 |
| LND, dichotomized | ||||||
| <18% | Reference | Reference | ||||
| ≥18% | 2.67 | 1.44–4.95 | 0.002 | 1.08 | 0.40–2.90 | 0.879 |
HR = hazard ratio; CI = confidence interval; UC = urothelial carcinoma; LVI = lymphovascular invasion; LND = lymph node density.